Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790912 | 0.94 | GRM5 (0.55) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL12691967 | 0.91 | ADORA1 (0.53) | GRM5ADORA1ADORA2AADORA2B | |
| SCHEMBL12694457 | 0.88 | GRM5 (0.67) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL12691985 | 0.84 | ADORA1 (0.49) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL12692087 | 0.84 | GRM5 (0.49) | GRM5ADORA1ADORA2AADORA2B | |
| SCHEMBL12694617 | 0.82 | GRM5 (0.61) | GRM5ADORA1ADORA2AADORA2B | |
| SCHEMBL12692066 | 0.79 | ADORA1 (0.53) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL12691994 | 0.79 | ADORA1 (0.53) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL12692153 | 0.77 | ADORA1 (0.46) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL12692085 | 0.77 | GRM5 (0.51) | GRM5ADORA1ADORA2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488519-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PF MEDICAMENT (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-8889711-B2 | Pyrazolopyridine derivatives as anticancer agent | PIERRE FABRE MEDICAMENT (FR) | 2014-11-18 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011045344-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | GRM5 3618/4885ADORA1 3012/4885ADORA2A 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.